| Marshall-kloene Orthopedic Inc | |
| 419 Tomahawk Dr, Maumee, Ohio 43537 | |
| (419) 893-0748 |
| Name | Marshall-kloene Orthopedic Inc |
|---|---|
| Organization Name | Marshall-kloene Orthopedics, Inc. |
| Location | 419 Tomahawk Dr, Maumee, Ohio 43537 |
| Type | DME Supplier - Customized Equipment |
| Phone | (419) 893-0748 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Structural cardiovascular abnormalities present at birth are the leading cause of heart failure in children. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA® (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product.
If you have hypertension, it pays to include a pharmacist in a medical care team. That's the upshot from research by the University of Iowa that found patients with uncontrolled hypertension had better blood pressure control when being cared for by pharmacists working in care teams (with a physician, for example) than patients who relied mostly on a doctor for medication guidance.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 5 days ago
| NPI Number | 1285616714 |
| Organization Name | MARSHALL-KLOENE ORTHOPEDICS, INC. |
| Type | DME Supplier - Customized Equipment |
| Address | 419 Tomahawk Dr, Maumee, OH 43537 |
| Phone Number | 419-893-0748 |
News Archive
Structural cardiovascular abnormalities present at birth are the leading cause of heart failure in children. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA® (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product.
If you have hypertension, it pays to include a pharmacist in a medical care team. That's the upshot from research by the University of Iowa that found patients with uncontrolled hypertension had better blood pressure control when being cared for by pharmacists working in care teams (with a physician, for example) than patients who relied mostly on a doctor for medication guidance.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 5 days ago
News Archive
Structural cardiovascular abnormalities present at birth are the leading cause of heart failure in children. Nearly half a million children in the United States have structural heart problems ranging in severity from relatively simple issues, such as small holes between chambers of the heart, to very severe malformations, including complete absence of one or more chambers or valves.
Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited has received pricing approval for NESINA® (alogliptin) in Japan. NESINA, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April 16, 2010. Furiex collaborated with Takeda to develop this product.
If you have hypertension, it pays to include a pharmacist in a medical care team. That's the upshot from research by the University of Iowa that found patients with uncontrolled hypertension had better blood pressure control when being cared for by pharmacists working in care teams (with a physician, for example) than patients who relied mostly on a doctor for medication guidance.
Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute's Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People's Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.
› Verified 5 days ago
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4062 Technology Dr, Maumee, Ohio 43537 Phone: (419) 471-1919 | |
Rite Aid Pharmacy 06679 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 105 Golden Gate Plz, Maumee, Ohio 43537 Phone: (419) 893-5533 | |
Pharmacy Counter Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1661 Holland Rd, Maumee, Ohio 43537 Phone: (419) 720-2005 | |
Kroger Pharmacy #525 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1435 Reynolds Rd, Maumee, Ohio 43537 Phone: (567) 302-2689 | |
Meijer Pharmacy #115 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1391 Conant Street, Maumee, Ohio 43537 Phone: (419) 891-8710 |